Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models

Katie E. Baker, Sara J. Bonvini, Chantal Donovan, Rachel E. Foong, Bing Han, Aruni Jha, Yasin Shaifta, Marieke Smit, Jill R. Johnson, Lyn M. Moir*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

28 Citations (Scopus)

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent respiratory diseases characterized by airway inflammation, airway obstruction and airway hyperresponsiveness. Whilst current therapies, such as beta-agonists and glucocorticoids, may be effective at reducing symptoms, they do not reduce disease progression. Thus, there is a need to identify new therapeutic targets. In this review, we summarize the potential of novel targets or tools, including anti-inflammatories, phosphodiesterase inhibitors, kinase inhibitors, transient receptor potential channels, vitamin D and protease inhibitors, for the treatment of asthma and COPD. (C) 2014 Published by Elsevier Ltd.

Original languageEnglish
Pages (from-to)181-198
Number of pages18
JournalPulmonary Pharmacology & Therapeutics
Volume29
Issue number2
DOIs
Publication statusPublished - Dec-2014

Keywords

  • Therapeutic targets
  • Kinase
  • G-protein coupled receptor
  • Transient receptor potential channel
  • Inflammation
  • Vitamin D
  • OBSTRUCTIVE PULMONARY-DISEASE
  • AIRWAY SMOOTH-MUSCLE
  • ACTIVATED PROTEIN-KINASE
  • PLACEBO-CONTROLLED TRIAL
  • NECROSIS-FACTOR-ALPHA
  • RANDOMIZED CONTROLLED-TRIAL
  • ALLERGEN-INDUCED INFLAMMATION
  • BETA-ADRENOCEPTOR AGONISTS
  • POTENTIAL ANKYRIN-1 TRPA1
  • VITAMIN-D SUPPLEMENTATION

Fingerprint

Dive into the research topics of 'Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models'. Together they form a unique fingerprint.

Cite this